Literature DB >> 6191139

Nifedipine reduces arrhythmias but does not alter prostanoid release during coronary artery occlusion and reperfusion in anaesthetised greyhounds.

S J Coker, J R Parratt.   

Abstract

We examined the effects of nifedipine, a calcium slow-channel blocking drug, on haemodynamics, blood gases, cardiac arrhythmias, and prostanoid release in anaesthetised greyhounds before, during, and after a 40-min occlusion of the left anterior descending coronary artery. Fifteen minutes after commencing treatment with nifedipine (5 micrograms/kg + 0.67 micrograms kg-1 min-1), there were significant reductions in arterial blood pressure, left ventricular end-diastolic pressure, and vascular resistance, with increases in cardiac output and stroke volume. Although coronary artery blood flow was unchanged, oxygen extraction was decreased, indicating that nifedipine reduced oxygen consumption. Nifedipine prevented the haemodynamic changes that occur in control dogs during acute myocardial ischaemia and markedly reduced the number of arrhythmias during coronary artery occlusion. The incidence of ventricular fibrillation induced by release of the occlusion was significantly reduced from 88% in the control group to 22% in the group receiving nifedipine. The release of thromboxane B2 and 6-keto PGF1 alpha (stable breakdown products of thromboxane A2 and prostacyclin, respectively) from the acutely ischaemic myocardium was not altered by nifedipine. It is concluded that this low dose of nifedipine had marked antiarrhythmic activity during both coronary artery occlusion and reperfusion. The relationship to dosage and possible mechanisms for this effect are discussed.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6191139     DOI: 10.1097/00005344-198305000-00010

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  9 in total

1.  Greater antiarrhythmic activity of acute 17beta-estradiol in female than male anaesthetized rats: correlation with Ca2+ channel blockade.

Authors:  K L Philp; M Hussain; N F Byrne; M J Diver; G Hart; S J Coker
Journal:  Br J Pharmacol       Date:  2006-08-29       Impact factor: 8.739

Review 2.  Role of calcium ions in reperfusion arrhythmias: relevance to pharmacologic intervention.

Authors:  L H Opie; W A Coetzee
Journal:  Cardiovasc Drugs Ther       Date:  1988-12       Impact factor: 3.727

3.  Proceedings of the British Pharmacological Society. 11th-13th April, 1984. Abstracts.

Authors: 
Journal:  Br J Pharmacol       Date:  1984-06       Impact factor: 8.739

4.  An investigation into the characteristics of reperfusion-induced arrhythmias in the anaesthetized rat and their susceptibility to antiarrhythmic agents.

Authors:  K A Kane; J R Parratt; F M Williams
Journal:  Br J Pharmacol       Date:  1984-06       Impact factor: 8.739

5.  Arrhythmia susceptibility and myocardial composition in diabetes. Influence of physical conditioning.

Authors:  S Bakth; J Arena; W Lee; R Torres; B Haider; B C Patel; M M Lyons; T J Regan
Journal:  J Clin Invest       Date:  1986-02       Impact factor: 14.808

6.  The effects of timolol on arrhythmias and prostanoid release during canine myocardial ischaemia and reperfusion.

Authors:  S J Coker; J R Parratt
Journal:  Br J Pharmacol       Date:  1984-04       Impact factor: 8.739

7.  AH23848, a thromboxane antagonist, suppresses ischaemia and reperfusion-induced arrhythmias in anaesthetized greyhounds.

Authors:  S J Coker; J R Parratt
Journal:  Br J Pharmacol       Date:  1985-09       Impact factor: 8.739

Review 8.  Combined receptor intervention and myocardial infarction.

Authors:  D A Chamberlain; R Vincent
Journal:  Drugs       Date:  1984       Impact factor: 9.546

9.  Calcium antagonists and acute myocardial ischemia: comparative effects of gallopamil and nifedipine on ischemia-induced and reperfusion-induced ventricular arrhythmias, epicardial conduction times, and ventricular fibrillation thresholds.

Authors:  H Gülker; W Haverkamp; G Hindricks; F Bender
Journal:  Cardiovasc Drugs Ther       Date:  1987-12       Impact factor: 3.727

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.